GlassScriptPhysician profile
Charles F Rilli
NPI 1639126485
$4,535.77
in general payments reported to CMS, 2019-2025
39 companies · $871 in 2025
The $871 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $214 · 2021: $559 · 2022: $650 · 2023: $788 · 2024: $749 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.33 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $666.53 | 2019-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $607.46 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $575.86 | 2019-2024 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $300.14 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $272.07 | 2022-2025 | |
| Abbvie INC. | $218.07 | 2019-2025 | Botox |
| Sumitomo Pharma America, INC. | $166.15 | 2023-2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $155.35 | 2020-2025 | Lynparza, Keytruda |
| Pfizer INC. | $138.27 | 2019-2025 | |
| Antares Pharma, INC. | $137.15 | 2025 | Xyosted |
| Tolmar, INC. | $117.78 | 2024-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $107.14 | 2021-2025 | |
| Coloplast Corp | $104.29 | 2019-2024 | |
| Verity Pharmaceuticals INC. | $98.33 | 2021-2023 | Trelstar |
| Ferring Pharmaceuticals INC. | $98.09 | 2019-2025 | Adstiladrin |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.